Measuring blood markers to monitor cancer treatment response
Official title: Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Run by Stanford University · NCT00349830 · Data updated 2026-11-12
This study is testing if certain blood markers can help doctors better understand how well cancer treatments are working for patients and predict their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Stanford, California) |
| Status | Recruiting |
| Started | January 2002 |
| Main results expected | January 2032 |
| Study ends | January 2032 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT00349830 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a prior diagnosis of cancer or those suspected of having cancer.
✕Probably not a fit
Patients who are not diagnosed with cancer or have a Karnofsky performance status of 70 or below may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and analyze blood serum from cancer patients and those suspected of having cancer at Stanford University. By measuring levels of serum proteins and other biomarkers, the study seeks to identify markers that can confirm diagnoses, predict responses to therapy, and assess relapse and survival rates. Blood samples will be collected before, during, and after anti-cancer therapy, and healthy individuals will also be included for comparison. The ultimate goal is to improve diagnostic and treatment strategies for various cancers.
Why it matters
Potential benefit: If successful, this study could lead to more accurate monitoring of cancer treatment responses and better personalized therapy options for patients.
How similar studies have gone: Other studies have shown promise in using serum biomarkers for cancer monitoring, indicating that this approach has potential based on previous findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
1. Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled. 2. Prior diagnosis of cancer or suspected of having cancer 3. Karnofsky performance status of greater than 70 4. Standard pretreatment evaluation 5. Signed Stanford University Human Subjects Committee consent
Where it's running
-
Stanford University School of Medicine
Stanford, California, United States Recruiting
Study contacts
- Principal investigator: Maximilian Diehn — Stanford University
- Study coordinator: gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
- Email: gitrialeligibility@stanford.edu
- Phone: 650-498-7757
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.